Author

Cécile Masson

Centre National de la Recherche ScientifiqueORCID 0000-0001-7870-7821Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Annarita MiccioiD· 2 shared Giuliana FerrariiD· 2 shared Mario AmendolaiD· 2 shared Oriana RomanoiD· 2 shared Pierre MartinucciiD· 2 shared Samantha ScaramuzzaiD· 2 shared Adélaïde Ferment· 1 shared Alexandra TachtsidiiD· 1 shared

Activity by Year

2022-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetics

Annarita MiccioORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyGastroenterologyPeer-reviewedApr 17, 2026

CLONAL LYMPHOCYTE EXPANSIONS AND JAK-STAT PATHWAY MUTATIONS DEFINE A PATHOGENIC CONTINUUM DRIVING RESISTANCE TO GLUTEN-FREE DIET IN CELIAC DISEASE

Georgia Malamut, Nicolas Guégan, Francesco Carbone…·Anaïs Levescot

This study identifies clonal lymphocyte expansions and JAK-STAT mutations in celiac disease subtypes, revealing shared mechanisms and limitations of JAK inhibitor therapy.

3 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky

GeneticsbioRxivPreprintAug 21, 2025

Base editing of β0 thalassemia mutations as a therapeutic strategy for β-hemoglobinopathies: efficacy and genotoxicity studies

Giulia Hardouin, Pierre Martinucci, Samantha Scaramuzza…·Annarita Miccio

Preclinical safety and efficacy studies of a new gene therapy approach for patients with severe β-hemoglobinopathies.

DOI 10.1101/2025.08.21.671453

humanexperimental assay

𝕏 PostBluesky

GeneticsbioRxivPreprintDec 31, 2022

Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies

Mégane Brusson, Anne Chalumeau, Pierre Martinucci…·Annarita Miccio

This study develops a bifunctional lentiviral vector for sickle cell disease that combines gene addition and gene silencing to reduce HbS levels and improve treatment efficacy.

2 citations

humanexperimental assay

𝕏 PostBluesky